Anavex Life Sciences (AVXL) Competitors $11.20 -0.10 (-0.88%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$11.15 -0.05 (-0.45%) As of 08/1/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AVXL vs. AKRO, ACLX, ACAD, VKTX, SWTX, SRRK, PTCT, PTGX, MLTX, and AAPGShould you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include Akero Therapeutics (AKRO), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), Viking Therapeutics (VKTX), SpringWorks Therapeutics (SWTX), Scholar Rock (SRRK), PTC Therapeutics (PTCT), Protagonist Therapeutics (PTGX), MoonLake Immunotherapeutics (MLTX), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Anavex Life Sciences vs. Its Competitors Akero Therapeutics Arcellx ACADIA Pharmaceuticals Viking Therapeutics SpringWorks Therapeutics Scholar Rock PTC Therapeutics Protagonist Therapeutics MoonLake Immunotherapeutics Ascentage Pharma Group International Anavex Life Sciences (NASDAQ:AVXL) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations. Do insiders and institutionals have more ownership in AVXL or AKRO? 31.6% of Anavex Life Sciences shares are held by institutional investors. 11.4% of Anavex Life Sciences shares are held by company insiders. Comparatively, 7.1% of Akero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend AVXL or AKRO? Anavex Life Sciences currently has a consensus target price of $44.00, suggesting a potential upside of 292.86%. Akero Therapeutics has a consensus target price of $82.50, suggesting a potential upside of 70.56%. Given Anavex Life Sciences' higher probable upside, equities analysts clearly believe Anavex Life Sciences is more favorable than Akero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anavex Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, AVXL or AKRO? Akero Therapeutics is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnavex Life SciencesN/AN/A-$43M-$0.55-20.36Akero TherapeuticsN/AN/A-$252.06M-$1.95-24.81 Is AVXL or AKRO more profitable? Akero Therapeutics' return on equity of -15.19% beat Anavex Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Anavex Life SciencesN/A -40.93% -36.38% Akero Therapeutics N/A -15.19%-13.97% Which has more volatility & risk, AVXL or AKRO? Anavex Life Sciences has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.28, indicating that its share price is 128% less volatile than the S&P 500. Does the media refer more to AVXL or AKRO? In the previous week, Anavex Life Sciences and Anavex Life Sciences both had 5 articles in the media. Akero Therapeutics' average media sentiment score of 1.29 beat Anavex Life Sciences' score of 0.64 indicating that Akero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Akero Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAnavex Life Sciences beats Akero Therapeutics on 7 of the 11 factors compared between the two stocks. Get Anavex Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVXL vs. The Competition Export to ExcelMetricAnavex Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$965.21M$2.99B$5.49B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-20.3617.7428.8623.83Price / SalesN/A178.75371.4866.02Price / CashN/A41.9535.4557.96Price / Book7.898.508.275.54Net Income-$43M-$55.06M$3.25B$259.28M7 Day Performance-7.67%-3.99%-3.73%-4.68%1 Month Performance5.96%9.58%4.29%4.36%1 Year Performance72.44%6.70%25.87%17.89% Anavex Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVXLAnavex Life Sciences3.7798 of 5 stars$11.20-0.9%$44.00+292.9%+70.2%$965.21MN/A-20.3640News CoverageUpcoming EarningsGap DownAKROAkero Therapeutics3.9559 of 5 stars$49.24-2.6%$82.50+67.5%+83.6%$3.93BN/A-25.2530Positive NewsUpcoming EarningsACLXArcellx2.6002 of 5 stars$70.59-1.0%$111.23+57.6%+21.3%$3.89B$107.94M-23.6180News CoveragePositive NewsAnalyst ForecastACADACADIA Pharmaceuticals3.9847 of 5 stars$22.62-2.7%$28.13+24.3%+23.9%$3.79B$996.28M16.51510News CoverageUpcoming EarningsAnalyst RevisionVKTXViking Therapeutics3.8674 of 5 stars$33.20-3.5%$86.92+161.8%-40.2%$3.73BN/A-21.7020Short Interest ↑SWTXSpringWorks TherapeuticsN/A$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230Upcoming EarningsSRRKScholar Rock3.8042 of 5 stars$37.09-4.8%$42.67+15.0%+301.3%$3.52B$33.19M-14.66140News CoverageUpcoming EarningsAnalyst ForecastPTCTPTC Therapeutics4.4901 of 5 stars$44.36-0.9%$65.77+48.3%+59.5%$3.52B$1.77B6.811,410Trending NewsUpcoming EarningsAnalyst ForecastAnalyst RevisionPTGXProtagonist Therapeutics2.1489 of 5 stars$56.26+2.0%$66.10+17.5%+41.8%$3.49B$207.80M75.01120Positive NewsUpcoming EarningsMLTXMoonLake Immunotherapeutics2.721 of 5 stars$54.47-1.1%$73.14+34.3%+25.9%$3.49BN/A-23.682News CoveragePositive NewsUpcoming EarningsAAPGAscentage Pharma Group InternationalN/A$39.27+3.9%N/AN/A$3.43B$134.35M0.00600 Related Companies and Tools Related Companies AKRO Alternatives ACLX Alternatives ACAD Alternatives VKTX Alternatives SWTX Alternatives SRRK Alternatives PTCT Alternatives PTGX Alternatives MLTX Alternatives AAPG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVXL) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anavex Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anavex Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
